Lupin Sees Oral Contraceptives Key To Growth In U.S. Generics Market
This article was originally published in PharmAsia News
Executive Summary
Lupin is pinning its future in the U.S. pharmaceutical market on its oral contraceptives, led in part by its yet-to-be-approved generic of Bayer Healthcare's Yaz and Yasmin (both drospirenone).